Antibody Therapies Set to Transform Respiratory Syncytial Virus Prevention for Babies
- Elie Dolgin
Access Resources
About
This article discusses the transformative potential of antibody therapies in preventing respiratory syncytial virus (RSV) infections in babies. The focus is on a specific antibody drug called nirsevimab, which offers protection against severe lung infections caused by RSV. Unlike traditional vaccines, nirsevimab is designed for prevention rather than treatment. The article explores the effectiveness, affordability, and accessibility of this new wave of antibody therapies, highlighting their potential to reduce hospitalizations due to RSV significantly. It also compares the benefits of antibody drugs versus maternal vaccination and discusses the importance of diverse RSV-preventing drugs to stay ahead of virus mutations.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.